Literature DB >> 22037032

The depression market.

Daniel Chancellor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22037032     DOI： 10.1038/nrd3585

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  3 in total

Review 1.  Major depressive disorder.

Authors:  R H Belmaker; Galila Agam
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

2.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

Review 3.  Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.

Authors:  Sidney H Kennedy; Sakina J Rizvi
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749
  3 in total
  5 in total

1.  Is the Chinese medicinal formula Guipi Decoction () effective as an adjunctive treatment for depression? A meta-analysis of randomized controlled trials.

Authors:  Chen-Xia Sheng; Ze-Qi Chen; Han-Jin Cui; A-Li Yang; Cong Wang; Zhe Wang; Nan-Xiang Su; Tao Tang
Journal:  Chin J Integr Med       Date:  2015-10-10       Impact factor: 1.978

2.  Meranzin Hydrate Improves Depression-Like Behaviors and Hypomotility via Ghrelin and Neurocircuitry.

Authors:  Ya-Lin Liu; Jian-Jun Xu; Lin-Ran Han; Xiang-Fei Liu; Mu-Hai Lin; Yun Wang; Zhe Xiao; Yun-Ke Huang; Ping Ren; Xi Huang
Journal:  Chin J Integr Med       Date:  2022-07-26       Impact factor: 2.626

3.  Searching the cytochrome p450 enzymes for the metabolism of meranzin hydrate: a prospective antidepressant originating from Chaihu-Shugan-San.

Authors:  Xi Huang; Ying Guo; Wei-Hua Huang; Wei Zhang; Zhi-Rong Tan; Jing-Bo Peng; Yi-Cheng Wang; Dong-Li Hu; Dong-Sheng Ouyang; Jian Xiao; Yang Wang; Min Luo; Yao Chen
Journal:  PLoS One       Date:  2014-11-26       Impact factor: 3.240

4.  Novel 1-(2-pyrimidin-2-yl)piperazine derivatives as selective monoamine oxidase (MAO)-A inhibitors.

Authors:  Betül Kaya; Leyla Yurttaş; Begüm Nurpelin Sağlik; Serkan Levent; Yusuf Özkay; Zafer Asim Kaplancikli
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

5.  Multi-modality: a new approach for the treatment of major depressive disorder.

Authors:  Elliott Richelson
Journal:  Int J Neuropsychopharmacol       Date:  2013-01-30       Impact factor: 5.176
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.